Victoza (liraglutide) is considered an injectable incretin mimetic. It is a relatively new drug used to treat type 2 diabetes. It is commonly mistaken with dulaglutide.
It is commonly recommended for adults and children over the age of 10 with type 2 diabetes to be used in conjunction with diet and lifestyle modifications to improve glycaemic control.
Incretin mimetics have been proven to be effective in lowering blood glucose. Clinical research studies have also been shown to be beneficial for weight loss compared to subjects on the placebo when used in combination with diet and exercise.
The FDA first approved Victoza for medical use in adults with type 2 diabetes in 2010 followed by approval in 2019 for the use in children older than ten years with type 2 diabetes. It has become the only non-insulin drug approved by the FDA to be used in the pediatric population since metformin was approved for pediatric use in 2000.
Victoza has been attached to other weight loss medications such as Trulicity and Ozempic.
Please note, Victoza does not replicate insulin vials, pens or cartridges.